Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...